The purpose of this study is to clarify the presence of so much insoluble microparticles in the injections and to conrm the usefulness of theˆnalˆlter for its removal. The test drugs used were Doyle1 g vial, Cefotax1 g vial, Minomycin100 mg vial, Omegacin0.3 g vial, Maxipime1 g vial, Rocephin1 g vial, Isovorin25 mg vial, Diamox500 mg vial and Fungizone50 mg vial. 1) An appropriate volume of physiological saline was poured into the test drug vial from the 500 ml physiological saline bag.
INTRODUCTION
Insoluble microparticles are occasionally detected in injection preparations. Although the 14th edition of the Japanese Pharmacopoeia determines tolerable ranges of the number of insoluble particles contained in injection preparations for quality control, 1) these tolerable ranges have not been su‹ciently validated.
There have been few studies that evaluated such insoluble microparticles in Japan, 2) and their eŠects on the body in the administration of large doses of drugs remain uncertain. 3 ) Therefore, we measured the number of insoluble microparticles contained in solutions of freeze-dried injection preparations to clarify the contents of microparticles in drugs of common clinical use and demonstrated that an infusionˆlter is useful for their removal.
MATERIALS AND METHODS
First, to select the infusion preparation with which lyophilized preparations would be dissolved, the number of insoluble microparticles was examined in a 100 ml polypropylene (PP) bag of physiologic saline and a 500 ml ethylene-vinyl acetate (EVAC) bag of physiologic saline (Terumo), which were available in this study.
Next, as shown in Table 1 , test solutions were prepared by dissolving 18 freeze-dried preparations of 6 antibiotics and 1 each of an anticancer agent, an antifungal agent, and a diuretic with diŠerent manufac- Test solutions were prepared by dissolving 27 freeze-dried preparations with diŠerent manufacturer's serial numbers. Each solution was collected 3 times, insoluble microparticles were counted.
Fig. 1. Methods of Preparing Each Test Solution
The freeze-dried preparations were dissolved by connecting a bag containing 500 ml of physiological saline with a vial containing a test preparation using a tube washed with water for injection, infusing an appropriate volume of it, and returning it to the infusion bag after conˆrmation of su‹cient dissolution of the drug. From the 500 ml bag of physiological saline containing a dissolved test drug, 100 ml was collected in a conical ‰ask as sample solution (1). Sample solution (2) was collected through an infusionˆlter (0.22 mm).
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Vol. 126 (2006) turer's serial numbers with 500 ml of physiological saline (Terumo). As shown in Fig. 1 , the freeze-dried preparations were dissolved by connecting a bag (ethylene-vinyl acetate; EVAC) containing 500 ml of physiological saline with a vial containing a test preparation using a tube washed with water for injec-tion prepared by ultraˆltration (experimental water), infusing an appropriate volume of physiological saline, and returning the saline to the infusion bag after conˆrmation of su‹cient dissolution of the drug. From the 500 ml bag of physiological saline containing a dissolved test drug, 100 ml was collected in a conical ‰ask as sample solution (1). Sample solution (2) was collected through an infusionˆlter (0.22 mm). Five milliliters of sample solutions (1) and (2) were collected 3 times, insoluble microparticles were counted, and the mean value was calculated for each solution. The number and size of insoluble microparticles were determined using a Model 8000 A automatic microparticle analyzer for liquids (Hiac/ Royco), which conformed to the method using a light-shielded type automatic microparticle counter prescribed by the Japanese Pharmacopoeia. Two lots of each drug were examined. The physiological saline was used afterˆltration with an infusionˆlter (0.22 mm). The conical ‰asks were used after they were washed with experimental water until no insoluble microparticles became observable. All procedures were carried out in a clean bench. The tube used to connect the infusion bag with the drug vial was Terufusiontube TC-00503 K (Terumo). The infusion lter was TerufusionFinal Filter PS TF SW231H
(Terumo) with a pore size of 0.22 mm. The infusion set was TS PA200L (Terumo) for the Terufusion pump. We also evaluated the number of insoluble microparticles derived from Terumo SS 10LZ 10 ml syringes (Terumo), which were disposable syringes routinely used for dissolving freeze-dried preparations in clinical practice.
RESULTS

Microparticles Derived from the Devices Used
The mean number of insoluble microparticles 5 mm or greater in 100 ml bags of physiological saline (Terumo; made of polypropylene (PP)), which is routinely used for dissolving freeze-dried preparations, was 12 ±3.3/5 ml. The mean number of insoluble microparticles 5 mm or greater in 500 ml EVAC bags of physiological saline was 1±0.5/5 ml. Next, the number of insoluble microparticles derived from disposable syringes routinely used for dissolving freeze-dried preparations was determined by aspirating 10 ml of saline with a 10 ml disposable syringe from a 100 ml bag (PP) of physiological saline, returning it to the same bag, and counting insoluble microparticles in the bag. The mean number of insoluble microparticles 5 mm or greater was 164±1.4/5 ml. Therefore, we dissolved freeze-dried preparations by connecting a 500 ml bag of physiological saline with a drug vial using a tube and counted insoluble microparticles in the solutions prepared by this method. As a result, the number of insoluble microparticles 5 mm or greater was 22±5.9/5 ml. However, when the tube that connected the saline bag and the drug vial was washed once with 20 ml of experimental water, no insoluble microparticle 5 mm or greater was observed in the solutions.
Number of Insoluble Microparticles in Freeze-dried Preparations Figure 2 shows the numbers of insoluble microparticles 5 mm or greater contained in 5 ml of 27 preparations of 9 freeze-dried drugs. The mean number of insoluble microparticles was largest at 250±45/5 ml in Doyle(ASPC), followed by 158 ±53/5 ml in Diamox(acetazolamide) and 129±29/ 5 ml in Fungizone (AMPH). These values are equivalent to 25000, 15800, and 12900 per 500 ml. Among the lowest values were 18±17/5 ml in Rocephin (CTRX) and 11±5/5 ml in Isovorin (levofolinate Ca). Still, these values are equivalent to 1800 and 1100 per 500 ml. The 6 antibiotics ranked in the number of insoluble microparticles in the order of ASPC＞CFPM＞BIPMCTX＞MINOCTRX.
Ability of the Infusion Filter to Remove Insoluble Microparticles
The number of insoluble microparticles 5 mm or greater in 5 ml of the solutions of the 27 preparations of 9 test drugs was 0-2/5 ml after they were passed through the infusionˆlter, indicating nearly complete elimination. When insoluble microparticles 2 mm or greater were counted, they were also removed by the infusionˆlter. Figure 3 shows an example with Rocephin (CTRX). Although the number of insoluble microparticles 5 mm or greater was smallest in Rocephin(CTRX) among all the freeze-dried preparations examined in this study, it contained many insoluble microparticles 2 mm or greater, most of which were also removed by an infusionˆlter (elimination rate: 95.6％).
DISCUSSION
The Japanese Pharmacopoeia requires tests of insoluble microparticles in all injection preparations. 1) According to the handbook for the 14th edition of the Japanese Pharmacopoeia (2001), the criteria of the number of insoluble microparticles are as follows: Each sample was collected 3 times, insoluble particles were counted, and the mean value was calculated. For injection preparations administered at 100 ml or more, the tolerated number of insoluble microparticles 10 mm or greater is 25 or less, and that of particles 25 mm or greater is 3 or less, per 1 ml. For injection preparations administered at less than 100 ml, the tolerated number of insoluble microparticles 10 mm or greater is 6000 or less, and that of particles 25 mm or greater is 600 or less, per container (method using a light-shielded type automatic microparticle counter) ( Table 2 ). However, no permissible range is shown concerning microparticles 10 mm or smaller. Although eŠects of microparticles on the body are not clear, intravenous injection of unnecessary materials should be avoided. Accidents due to incompatibility of calcium phosphate 4) and death due to pulmonary embolism by glass fragments considered to be derived from cutting of ampoules 5) have been reported. The British Pharmaceutical Nutrition Group Working Party (BPNG) has issued a guideline from a viewpoint of avoiding stressing human bodies with insoluble microparticles. 6) In these circumstances, the National Coordinating Committee on Large Volume Parenterals (NCCLVP), Intravenous Nurses Society (INS), and Food and Drug Administration (FDA) of the United States have recommended incorporation of aˆnalˆlter in the IV line for intravenous administration of drugs. In Japan, also, there are guidelines requiring incorporation of aˆnalˆlter in the IV line. [7] [8] [9] However, the guideline of the Centers for Disease Control and Prevention (CDC) 10) does not explicitly acknowledge the signiˆcance of theˆnal lter. It must be remembered that this recommendation was issued in the medical background of the United States, where preparations for Total Parenteral Nutrition (TPN) are provided to clinical departments after removing bacteria, foreign bodies, and insoluble microparticles at the pharmacy. An infusion lter is considered to be absolutely necessary in Japan, where TPN ‰uids are prepared in the ward or are mixed with many other drugs via a 3 way stopper. While aˆnalˆlter is considered to be useful for elimination of insoluble microparticles in Japan, data that support this view have not been reported after Uchida et al. in 1979. 11) We, therefore, clariˆed the presence of insoluble microparticles in injection preparations and evaluated the usefulness of an infusionˆlter for its removal.
First, since insoluble microparticles derived from the devices must be eliminated, conditions for their elimination were evaluated. As mentioned above, we carried out experiments by completely eliminating insoluble microparticles derived from instruments. Also, our experiment indicated that 500 ml bags (made of EVAC) of physiological saline used for dissolving drugs contain very few insoluble microparticles 5 mm or greater. We consider that insoluble microparticles other than those contained in the drugs could be completely eliminated in this study by: 1) not using disposable syringes and connecting the saline bag and drug vial with a tube washed with ex-perimental water, 2) using instruments for the collection of sample solutions after washing them with experimental water, and 3) selecting infusion vehicles used for dissolving drugs from those with minimum contents of insoluble microparticles.
Concerning the number of insoluble microparticles derived from the devices used, the mean value was 12 ±3.3 particles/5 ml in the 100 ml PP bag of physiologic saline and was higher than the value for the 500 ml EVAC bag of physiologic saline (1 particle/5 ml). Also, the number of insoluble microparticles was the smallest in the 500 ml EVAC bag of physiologic saline among all the infusion preparations examined in this study. Therefore, we used a 500 ml EVAC bag of physiologic saline to dissolve the lyophilized preparations, although this combination is unlikely in clinical practice. The objective of this selection was to minimize the eŠect of insoluble microparticles in the infusion preparation and to exclusively evaluate insoluble microparticles contained in drugs. The diŠer-ences in the number of insoluble microparticles observed in this study were caused by diŠerences in the manufacturing line in the factory rather than diŠer-ences in the bag material. Also, among the mean numbers of insoluble microparticles derived from the devices used for the dissolution of lyophilized preparations, that observed after the manipulation of the 10 ml disposable syringe was high at 164±1.4/5 ml. This time, the identiˆcation of these insoluble microparticles was not done. However, we guess that a lot of TPE (Thermoplastic Elastmers), silicon oil and the others were included in them. Therefore, it was not used in this study. Moreover, to eliminate the small number of insoluble microparticles derived from devices, the connecting tube was used after washing it with water for injection prepared by ultraˆltration to remove all insoluble microparticles.
Concerning the numbers of insoluble microparticles in the lyophilized preparations, a wide variation was observed, but all samples contained many insoluble microparticles derived from the preparations (Fig. 2) . Since the sample volume was 5 ml, the total number of insoluble microparticles derived from preparations was estimated to be as high as 25000 in ASPC, 8100 in CFPM, and 3700 in BIPM, and to be 1800 even in CTRX, which contained the smallest number of insoluble microparticles among the 6 antibiotics. Also, if the preparations had been dissolved with a 100 ml bag of physiologic saline, even greater numbers of insoluble microparticles might have resulted. This means that contamination by insoluble microparticles may be aggravated if drugs including lyophilized preparations are mixed in a single infusion preparation. While these values are surprisingly high, they still meet the criteria of the Japanese Pharmacopoeia concerning insoluble microparticles, which are not softer than those of foreign pharmacopoeias. However, in consideration of the situation in Japan whereby multiple drugs are more often mixed in a single infusion preparation for administration than in foreign countries, a stricter revision of the Japanese Pharmacopoeia may be necessary.
Concerning the ability of the infusionˆlter to eliminate insoluble microparticles, it almost completely removed those derived from lyophilized preparations, as was expected. In CTRX, for example, the elimination rate was 95.6％. These results conˆrmed that the use of an infusionˆlter is eŠective for the elimination of insoluble microparticles derived from preparations contaminating infusion preparations.
In this study, insoluble microparticles 5 mm or greater were evaluated, because there have been reports that particles of this size may obstruct arterioles and capillaries. 12, 13) Also, it became clear that insoluble microparticles less than 5 mm are contained in greater numbers. Although whether these insoluble microparticles were undissolved components of drugs or foreign bodies that entered in the manufacturing process was not determined, they were shown to be eliminated nearly completely by passing the solutions of drugs through an infusionˆlter. These results suggest that incorporation of aˆnalˆlter in the IV line is necessary not only for the prevention of bacterial infections but also for elimination of insoluble microparticles. The Japanese Pharmacopoeia prescribes the criteria for insoluble microparticles 10 mm or greater and those 25 mm or greater, but the special report of the ASPEN 12) recommends attention to particles 5 mm or greater. In addition, the number of insoluble microparticles may increase if the drug has been dissolved with 100 ml of a vehicle. We, therefore, demand a revision of the Japanese Pharmacopoeia concerning the testing methods for insoluble microparticles. In the present state, however, we propose the incorporation of aˆnalˆlter into the IV line in intravenous administration of drugs to eliminate insoluble microparticles derived from drugs, manufacturing processes, and devices such as the disposable syringe, regardless of the quantity of administration.
CONCLUSION
These results suggest that incorporation of aˆnal lter in the IV line is extremely necessary not only for the prevention of bacterial infections, but also for elimination of insoluble microparticles.
